Dhanuka Agritech Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 4 Aug 2026 | Fertilizers & Agrochemicals | Market Cap: ₹4.5K Cr
Dhanuka Agritech expects healthy double-digit growth over the next 3 to 5 years. Dhanuka Agritech expects healthy double-digit growth over the next 3 to 5 years, driven by favorable macroeconomic factors and increased value-added crop cultivation.
From Dhanuka Agritech Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹980
Market Cap
₹4.5K Cr
P/E Ratio
16.7
How does Dhanuka Agritech Ltd rank in Fertilizers & Agrochemicals?
Compare Dhanuka Agritech Ltd against every Fertilizers & Agrochemicals company this quarter on revenue, margins and earnings-call signals.
Dhanuka Agritech Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹483 Cr, net profit ₹98 Cr.
Full financials →📊 Revenue & Sales Performance
- →Dhanuka Agritech expects healthy double-digit growth over the next 3 to 5 years.
- →Growth drivers include expansion in existing products, new molecules, exports, and entry into new crops.
- →Favorable macroeconomic factors boost agriculture and agri-input industries.
- →Increasing multiple crop cycles per year due to better irrigation and marketability of produce.
- →Agrochemical consumption in India is low (~600 grams/hectare) compared to world averages, indicating significant growth potential.
- →The company focuses on specialized, value-added crops (grapes, tomato, chilli) as well as conventional crops (rice, soybean, cotton, tea).
- →Growth depends on better reach to every cultivating field and intensifying market penetration.
- →Q4 shows promise of growth, but full year may be flattish for short term.
- →Expansion in technical sales expected (10-20% growth next year).
- →New product launches scheduled for FY'27 targeting high-value crops.
📈 Profitability & Margins
- →Dhanuka Agritech expects healthy double-digit growth over the next 3 to 5 years, driven by favorable macroeconomic factors and increased value-added crop cultivation.
- →Growth will stem from existing products, new molecules, exports, and entry into new crops, supported by expanded multiple crop cycles and improved irrigation.
- →The company anticipates continued expansion due to low current agrochemical consumption and a large arable land base in India.
- →EBITDA margins guided around 18% for 9 months, with slight expected contraction of 100-110 bps annually.
- →Sustainable gross margin is expected around 38%, down from recent highs (~40%) due to normalization after net economic benefits.
- →Bayer product contributions will align with overall gross margins (~40%), with Q4 expected to show growth but full year expected to be flattish.
- →New product launches and improved product mix support growth trajectory.
🏗️ Capital Expenditure Plans
- →For FY'27, Dhanuka Agritech is commissioning an MPP-2 plant with an expected CAPEX of Rs. 60-70 crores.
- →The MPP-2 plant will produce three products, including Bifenthrin, Difenoconazole, and a new product Iprovalicarb, targeting 80% capacity utilization next year.
- →Discussions are ongoing with multinational players, including one Japanese and one European company, for potential exclusive contract manufacturing or strategic partnerships at the Dahej manufacturing facility.
💰 Fundraising & Capital Structure
- →There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript.
- →Management discusses ongoing investments, such as CAPEX of Rs. 60-70 crores for the MPP-2 plant but does not specify funding sources.
- →Current cash on books is more than Rs. 250 crore, and the company has reduced bank loans from Rs. 50 crore.
- →No references to plans for raising debt or equity capital have been made.
- →Discussions largely focus on operational aspects, product launches, and market expansion without indicating upcoming fundraising activities.
📋 Order Book & Pipeline
Key Metrics
Continue your research
What Dhanuka Agritech's management said in earlier quarters
Others in Fertilizers & Agrochemicals this season
- Indogulf Cropsci (Q3 FY26)
The value of these export orders in hand is approximately INR 4 to 5 crores. Key concall takeaways from Indogulf Cropsci's Q3 FY26 earnings call — and how it…
- Rallis India (Q3 FY26)
Domestic B2C business growing steadily with 13% growth in Q3; volume expansion despite some price softness. Key concall takeaways from Rallis India's Q3 FY26…
- Sharda Cropchem Ltd (Q3 FY26)
Capex planned in the range of INR 450-500 crores to support growth and registration activities. Key concall takeaways from Sharda Cropchem Ltd's Q3 FY26…
- Krishana Phoschem Ltd (Q3 FY26)
It is noted that manufacturing is operating at almost 100% capacity and the company is importing to meet excess demand. Key concall takeaways from Krishana…
Frequently Asked Questions
What were Dhanuka Agritech Ltd Q3 FY26 results?
Dhanuka Agritech expects healthy double-digit growth over the next 3 to 5 years. Dhanuka Agritech expects healthy double-digit growth over the next 3 to 5 years, driven by favorable macroeconomic factors and increased value-added crop cultivation.
What is Dhanuka Agritech Ltd share price analysis?
Dhanuka Agritech Ltd currently shows a neutral. The stock trades at a P/E of 16.7 with a market cap of ₹4,482 Cr. Investors should review the full earnings analysis for detailed insights.
Is Dhanuka Agritech Ltd planning capital expenditure?
For FY'27, Dhanuka Agritech is commissioning an MPP-2 plant with an expected CAPEX of Rs.
Keep Dhanuka Agritech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.